High doses of NAC (N-acetylcysteine): Mucolytic and antioxidant activities;Proprietà mucoattive ed antiossidanti della NAC (N-acetilcisteina) ad alte dosi

GIMT - Giornale Italiano delle Malattie del Torace

Volumn 56, Issue 3, 2002, Pages 193-202

  Allegra, L ^a   Blasi, F ^a   Capone, P ^a   Centanni, S ^a   Cogo, R ^a   Damato, S ^a   Petrigni, G ^a   Piatti, G ^a   Rampoldi, C ^a   Rizzato, G ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Antioxidant activity; COPD; High doses; Mucolytic activity; N acetylcysteine

Indexed keywords

ACETYLCYSTEINE; ANTIOXIDANT; MUCOLYTIC AGENT; PEROXIDASE;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; EXPIRATORY RESERVE VOLUME; FEMALE; FLOW KINETICS; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; SCORING SYSTEM; SMOKING; SPUTUM ANALYSIS; TREATMENT INDICATION; VISCOSITY; VITAL CAPACITY;

EID: 0036961990     PISSN: 11270810     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Allegra L, Crystal RG, Grassi C. GSH System: Glutathione in Antioxidant Defense. Excerpta medica, Amsterdam 1992.
2. Allegra L, Moavero NE, Rampoldi C. Ozone-induced impairment of mucociliary transport and its prevention with N-acetylcisteine. Am J Med, 91 (suppl. 3C): 67-71, 1991.
3. Arouma OI, Halliwell B, Hoey BM, Butler J. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Rad Biol Med, 6: 583-7, 1989.
4. MacNee W, Bridgeman MME, Marsden M, Drost E, Lannan S, Selby C, Donaldson K. The effect of N-acetylcysteine and glutathione on smoke-induced changes in lung phagocytes and epithelial cells. Am J Med, 91 (suppl. 3C): 60-66, 1991.
5. Lundbäck B, Lindstrom M, Anderssar S, Nyström L, Rosenhall L, Stjernberg N. Possible effect of acetylcystein on lung function. Eur. Respir. J, 5 (suppl 15):289s,1992 (abstract)
6. De Benedetto F, Aceto A, Formisano S, Spacone A, Pela R, Dragani B, Cocco R, Marchesani F, Jacoacci C, Sanguinetti C.M. Long-term treatment with N-acetylcysteine (NAC) decreases hydrogen peroxide level in the exhaled air of patients with moderate COPD. Monaldi Arch. Chest Dis, 55:185-8,2000
7. Kazielski M, Nowak D. Long-term administration of N-acetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease. Respir. Med, 95: 448-56, 2001.
8. Schmid G, Li Bianchi E, Straface E, Vitto M, Matarrese P, Gambardella L, Mariotta S, Fiorucci F, Ricci A, Malorni W. N-acetylcysteine (NAC) counteracts erytrocyte damages and is useful in management of COPD. Am J Respir Crit Care Med, 165 (suppl), 2002 (abstract).
9. Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest, 108: 43s-52s, 1995.
10. Allegra L, Grassi C, Grossi E. Ruolo degli antibiotici nel trattamento della bronchite cronica: risultati di uno studio italiano multicentrico. Giorn It Mal Tor, 45: 138-148, 1991.
11. Braga PC, Allegra L, Dall'Oglio G, Angelini M, Mocchi A. A new rheometer with special features designed for bronchial mucus analysis in clinical practice. Biorheol, 29: 285-293, 1992.
12. Cesarone MR, Belcaro G, Carratelli M, Cornelli U, De Sanctis MT, Incandela L, Barsotti A, Terranova R, Nicolaides A. A simple test to monitor oxidative stress. Intern Angiol, 18: 127-30, 1999.
13. Allegra L, Blasi A, Capone P, Centanni S, Cogo R, Damato S, Petrigni G, Piatti G, Rampoldi C, Rizzato G. Ottimizzazione dei dosaggi della NAC per l'espressione delle sue proprietà mucolitiche ed antiossidanti. Giorn It Mal Tor, 55: 476-484, 2001.
14. Rizzato G. Le Nuove Frontiere della Terapia con Antiossidanti: N-acetilcisteina. EffeEdizioni, Verona 2001.
15. Grandjean E, Berthet P, Ruffmann R, Leuenberger P. Efficacy of oral long term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind placebo controlled trials. Clin Ther, 22: 209-21, 2000.
16. Stey C, Steurer J, Bachmann S, Medici TC, Trauner MR. The effect of oral N-acetylcysteine in chronic bronchitis. A quantitative systematic review. Eur Respir J, 16: 253-62, 2000.
17. Tepel M, van der Giet M, Schwartzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic contrast agent-induced reductions in renal function by acetylcysteine. New Engl J Med, 343: 210-2, 2000.
18. Safirstein R, Andrade L, Vieira J. Acetylcysteine and nephrotoxic effects of radiographic contrast agents: a new use of an old drug. New Engl J Med, 343: 180-4, 2000.
19. Montanini S, Sinardi D, Pratico C. Use of acetylcysteine as the life-saving antidote in Amanita Phalloides (death cap) poisoning; case report of 11 patients. Arzneimittelfrsch, 49: 1044-7, 1999.
20. Hashimoto S, Gon Y, Takeshita I, Matsumoto K, Jibiki I, Takizawa H, Kudoh S, Orie T. Diesel exhaust particles activate p38 MAP kinase to produce interleukin-8 and RANTES by human bronchial epithelial cells and N-acetylcysteine attenuates p38 MAP kinase activation. Am J Respir Crit Care Med, 161: 280-5, 2000.
21. Ortolani O, Conti A, De Gaudio A, Moraldi E, Contini O, Novelli G. The effect of glutathione and N-acetylcysteine on lipoperoxidative damage in patients with early septic shock. Am J Respir Crit Care Med, 161: 1907-11, 2000.
22. Ortolani O, Conti A, De Gaudio A, Masoni M, Novelli G. Protective effects of N-acetylcysteine and rutin on the lipid peroxidation of the lung epithelium during the adult respiratory distress syndrome. Shock, 113: 14-8, 2000.
23. Rank N, Michel C, Haertel C, Lenhart A, Welte M, Meyer-Hellmann A, Spies C. N-acetylcysteine increases liver blood flow and improves liver function in septic shock patients: results of a prospective, randomized, double blind study. Crit Care Med, 28: 3799-807, 2000.
24. Hagiwara S, Ishii Y, Kitamura S. Aerosolized administration of N-acetylcysteine attenuates lung fibrosis induced by bleomicin in mice. Am J Respir Crit Care Med 162: 225-31, 2000.
25. Ringden O, Remberger M, Lehmann S, Hentschke P, Mattsson J, Klaesson S, Aschan J. N-acetylcysteine for hepatic veno-occlusive disease after allogenic stem cell transplantation. Bone Marrow Transplant, 25: 993-6, 2000.
26. Straface E, Matarrese P, Gambardella L, Forte S, Carlone S, Libianchi E, Schmid G, Malorni W. N-acetylcysteine counteracts erythrocyte alterations occuring in chronic obstructive pulmonary disease. Biochem Biophys Res Comm, 279: 552-6, 2000.
27. Andrews N, Prasad A, Quuyyumi A. N-acetylcysetine improves coronary and peripheral vascular function. J Am Coll Cardiol, 37: 117-23, 2001.
28. Khuri F, Lippman S. Lung cancer chemoprevention. Semin Surg Oncol, 18: 100-5, 2000.
29. Goldman D, Peled A, Shinitzky M. Effective elimination of lung metastases induced by tumor cells treated with hydrostatic pressure and N-acetylcysteine. Cancer Res, 60: 350-8, 2000.
30. Cavallini L, Alexandre A. Oral N-acetylcysteine increases the production of anti HIV chemokines in peripheral blood mononuclear cells. Life Sci, 67: 147-54, 2000.
31. Muller F, Svardal A, Nordoy I, Berge RK, Aukrust P, Froland SS. Virological and immunological effects of antioxidant treatment in patients with HIV infection. Eur J clin Invest, 30: 905-14, 2000.
32. De Rosa S, Zaretsky M, Dubs J, Roederer M, Anderson M, Green A, Mitra D, Watanabe N, Nakamura H, Tjioe I, Deresinski SC, Moore WA, Ela SW, Parks D, Herzenberg LA. N-acetylcysteine replenishes glutathione in HIV infection. Eur J Clin Invest, 30: 915-29, 2000.
33. De Flora S, Grassi C, Carati L. Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment. Eur Respir J, 10: 1535-41, 1997.
34. Harrison P, Keays R, Bray G, Alexander GT, Williams R. Improved outcome in paracetamol-induced hepatic failure following late administration of N-acetylcysteine. Lancet, 335: 1572-3, 1990.
35. Keays R, Harrison P, Wendon J, Forbes A, Gove C, Alexander GT, Williams R. Intravenous acetylcysteine in paracetamol-induced furlminant hepatic failure: a prospective controlled trial: BMJ, 303: 1026-9, 1991.
36. Harrison P, Wendon J, Gimson AE, Alexander GT, Williams R. Improvement by acetylcysteine of haemodynamics and oxygen transport in fulminant hepatic failure. New Engl J Med, 334: 1852-7, 1991.
37. Insel P. Para-aminophenol derivatives: acetaminophen. In: Hardman J and Limbird L. Goodman & Gilman's Pharmacological Basis for Therapeutics. McGraw Hill, New York, 631-3, 1996.
38. Gow P, Smallwood R, Angus P. Paracetamol and liver transplantation. J Gastroenterol Hepatol, 14: 817-21, 1999.
39. Holt S, Goodier D, Marley R, Patch D, Burroughs A, Fernando B, Harry D, Moore K. Improvements in renal function in hepatorenal syndrome with N-acetylcysteine. Lancet, 353: 294-5, 1999.
40. Holoye P, Duelge J, Hansen RM, Ritch PS, Anderson T. Prophylaxis of ifosfamide toxicity with oral acetylcysteine. Sem Oncol, 10: 66-71, 1983.
41. Moldeus P, Cotgreave I, Berggren M. Lung protection by a thiol- containing antioxidant: acetylcysteine. Respiration, 50 (suppl. 1): 31-42, 1986.
42. Gressier B, Cabanis A, Lebègue S, Brunet C, Dine T, Luickx M, Cazin M, Cazin JC. Decrease of hypochlorous acid and hydroxyl radical generated by stimulated human neutrophils: camparison in vitro of some thiol-containing groups. Methods Find Exp Clin Pharmacol, 16: 9-13, 1994.
43. Bridgeman MM, Marsden M, McNee W, Flenley DC, Ryle AP. Cysteine and glutathione concentrations in plasma and BAL fluid after treatment with N-acetylcysteine. Thorax, 46: 39-42, 1991.
44. Linden M, Wieslander E, Eklund A, Larsson K, Brattsand R. Effects of oral N-acetylcysteine on cell content and macrophage function in BAL from healthy smokers. Eur Respir J, 1: 645-50, 1988.
45. Bridgeman MM, Marsden M, Selby C, Morrison D, McNee W. Effect of N-acetylcysteine on the concentrations of thiols in plasma, BAL fluid and lung tissue. Thorax, 49: 670-5, 1994.
46. Poole P, Black P. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systemic review. BMJ, 322: 1271-4, 2001.
47. Allegra L, Dal Sasso M, Bovio C, Massoni C, Fonti C, Braga PC. Human neutrophil oxidative bursts and their in vitro modulation by different N-acetylcysteine concentrations. Arzneimittelfrsch (in corso di stampa): pubblicazione annunciata entro il 2002.
48. Villarasa V, Cortijo J, Marti Cabrera M, Ortiz JL, Berto L, Esteras A, Bruseghini L, Morcillo EJ. Inhibitory effects of N-acetylcysteine on superoxide anion generation in human polymorphonuclear leukocytes. J Pharmacol, 49: 125-9, 1997.
49. Gressier B, Cabanis A, Lebègue S, Brunet C, Dine T, Luickx M, Cazin M, Cazin JC. Comparison of in vitro effects of two thio-containing drugs on human neutrophils hydrogen peroxide production. Methods Find Exp Clin Pharmacol 15: 101-5, 1993.
50. Paulsen O, Forsgren A. Effects of N-acetylcysteine on human polymorphonuclear leukocytes. APMIS, 97: 115-9, 1989.
51. Udupi V, Rice-Evans C. Thiol compounds as protective agents in erytrocytes under oxidative stress. Free Rad Res Comm, 16: 315-23, 1992.
52. Soriani M, Pietraforte D, Minetti M. Antioxidant potential on anaerobic human plasma: role of serum albumin and thiols as scavengers of carbon radicals. Arch Biochem Biophys, 312: 180-8, 1994.